Prostate CancerPhase 4NCT02773251
The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
A Phase 4 study testing hyaluronic acid-carboxymethylcellulose in people with Prostate Cancer and Postoperative Adhesion, run by Bucheon St. Mary's Hospital.
Trial summary
To assess the anti-adhesive effect of treatment with hyaluronic acid-carboxymethylcellulose following laparoscopic pelvic surgery (radical prostatectomy). Read more about this study
- Who is it for?
- Ages 50 to 75 years, men only
- Conditions the study is for
- Prostate Cancer, Postoperative Adhesion
- What is being tested?
- hyaluronic acid-carboxymethylcellulose
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Nov 2011to Jun 2014
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic pelvic surgery (radical prostatectomy).
Who cannot join
- any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.
About this study
Official title: Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study
To assess the anti-adhesive effect of treatment with hyaluronic acid-carboxymethylcellulose following laparoscopic pelvic surgery (radical prostatectomy).
Read the detailed description
Methods This was a prospective, randomized, controlled, single-blind, parallel-group study using HA/CMC (marketed as Guardix-sol®, Hanmi Medicare, Seoul, Korea) in patients who underwent laparoscopic radical prostatectomy between November 2011 and June 2014. All the patients were informed in detail about the aims and the procedures of the study and they signed a written informed consent prior inclusion into the study. The protocol and the written informed consent were approved by the local ethical committee (Catholic Medical Center, Clinical Research Coordinator Center; approval number XC11DIMI10098H).
Subjects Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic radical prostatectomy. Exclusion criteria included any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.
Study design and protocol The laparoscopic radical prostatectomy was performed in same surgical procedures and steps by two surgeons (USH and JSK) who have experienced over 150 cases of laparoscopic radical prostatectomy. The laparoscopic radical prostatectomy was performed using the five-port fan-shaped transperitoneal approach. After the introducing the peritoneal cavity, incising the parietal peritoneum between the medial umbilical ligaments are incised and dissection is carried through the fatty alveolar tissue to develop the space of Retzius. After that, the surgical steps are following order (1) incision of the endopelvic fascia; (2) ligation of the dorsal vein complex; (3) division of the bladder neck; (4) dissection of the seminal vesicles; (5) incision of the Denonvillier fascia and control of the lateral pedicles with antegrade neurovascular bundle dissection; (8) apical dissection and division of the dorsal vein and the urethra; (9) urethrovesical anastomosis.
Considering about 30% of dropout rate (under the assumption of 40% difference between HA/CMC treatment group and the control group based on previous similar study, by which the target enrollment for this trial was 60 subjects (30 subjects per group). The sample size was determined assuming a level of significance of α=0.05 (two-side) and a 80% statistical power of test. All patients were randomly assigned to either the HA/CMC treatment group (n=30) or the control group (n=30) using a computer-generated randomization table. The surgeon was blinded to treatment assignments before randomization. Patients were also blinded to their treatment group throughout the study. HA/CMC was applied in all port sites and the peritoneal incision line of the medial umbilical ligament with a single-use applicator attached to a sprayer that allowed for the precise application to the required sites. The amount of HA/CMC applied was 5 ml. Information regarding the duration of illness and medical history were collected at the time of enrollment (V0). Viscera slide ultrasound and plain X-ray were recorded at the time of the operation (V0) and 12 (V1) and 24 week (V2) after the operation.
The primary end point was the difference in excursion distance on viscera slide ultrasound between V0 and V2. The secondary end point was excursion distance on viscera slide ultrasound at V2 and the presence of restriction of viscera slide on ultrasound at V2.
Assessment of efficacy and safety Twelve and 24 weeks after the operation, bowel adhesion to the abdominal wall was evaluated by ultrasound and plain X-rays. We performed viscera slide ultrasound according to a technique that has been previously described. By dividing the abdomen into 5 segments and examining the viscera slide in each segment, a prediction of the extent of the adhesions was made for each patient. At the time of the viscera slide ultrasound, data were also collected on the location of the scars on the abdomen. The main point of interest was the distance of the longitudinal excursion of the selected area in relation to the fixed abdominal wall. Normal viscera sliding movement was defined as equal to or greater than 1 cm of longitudinal movement. Restricted viscera slide was defined as less than 1 cm of longitudinal movement during both normal and exaggerated respiration. The ultrasound was performed by two sonographers who had been well instructed for study assessment. The assessment by ultrasound was double-checked. The sonographer, radiologist and all accessor was blind to the randomization during the all study period.
Statistical Analysis The data for this study are expressed as mean ± standard deviation of the mean. The comparisons of the 2 groups were made using a chi-test, an independent Student's t test, or repeated measure ANOVA. P-values <0.05 were considered significant. Statistical calculations were carried out with IBM SPSS statistics, Version 21 (IBM Corp, Armonk, NY).
- Conditions
- Prostate Cancer, Postoperative Adhesion
- Being tested
- hyaluronic acid-carboxymethylcellulose
- Keywords
- Postoperative adhesion, Laparoscopy, Adhesion barrier
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
hyaluronic acid-carboxymethylcelluloseDrug
| Study group | Role | What they receive |
|---|---|---|
| hyaluronic acid-carboxymethylcellulose treatment group | Experimental | the HA/CMC treatment group after laparoscopic pelvic surgery Receives: Drug: hyaluronic acid-carboxymethylcellulose |
| control group | No intervention | the HA/CMC non-treatment group after laparoscopic pelvic surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
the difference in excursion distance on viscera slide ultrasound between V0 and V2.
Measured: within the first 6 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2016 (estimated)
- Study startNov 2011
- Primary completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bucheon St. Mary's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Koh Jun Sung, Bucheon St. Mary's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02773251
- Sponsor's protocol ID
- XC11DIMI10098H
- Status last verified
- May 2016
- First submitted
- 12 May 2016
- Last updated
- 17 May 2016
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Ha US, Koh JS, Cho KJ, Yoon BI, Lee KW, Hong SH, Lee JY. Hyaluronic acid-carboxymethylcellulose reduced postoperative bowel adhesions following laparoscopic urologic pelvic surgery: a prospective, randomized, controlled, single-blind study. BMC Urol. 2016 Jun 10;16(1):28. doi: 10.1186/s12894-016-0149-3.
PubMed 27286961
Study at a glance
From the registry record, last updated by the sponsor on 17 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study
- ClinicalTrials.gov ID
- NCT02773251
- Acronym / sponsor ID
- XC11DIMI10098H
- Conditions
- Prostate Cancer, Postoperative Adhesion
- Keywords
- Postoperative adhesion, Laparoscopy, Adhesion barrier
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Bucheon St. Mary's HospitalUniversity, hospital or other
- Study start
- Nov 2011
- Primary completion
- Jun 2014 (actual)
- First posted
- 16 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the anti-adhesive effect of treatment with hyaluronic acid-carboxymethylcellulose following laparoscopic pelvic surgery (radical prostatectomy).
Detailed description
Methods This was a prospective, randomized, controlled, single-blind, parallel-group study using HA/CMC (marketed as Guardix-sol®, Hanmi Medicare, Seoul, Korea) in patients who underwent laparoscopic radical prostatectomy between November 2011 and June 2014. All the patients were informed in detail about the aims and the procedures of the study and they signed a written informed consent prior inclusion into the study. The protocol and the written informed consent were approved by the local ethical committee (Catholic Medical Center, Clinical Research Coordinator Center; approval number XC11DIMI10098H).
Subjects Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic radical prostatectomy. Exclusion criteria included any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.
Study design and protocol The laparoscopic radical prostatectomy was performed in same surgical procedures and steps by two surgeons (USH and JSK) who have experienced over 150 cases of laparoscopic radical prostatectomy. The laparoscopic radical prostatectomy was performed using the five-port fan-shaped transperitoneal approach. After the introducing the peritoneal cavity, incising the parietal peritoneum between the medial umbilical ligaments are incised and dissection is carried through the fatty alveolar tissue to develop the space of Retzius. After that, the surgical steps are following order (1) incision of the endopelvic fascia; (2) ligation of the dorsal vein complex; (3) division of the bladder neck; (4) dissection of the seminal vesicles; (5) incision of the Denonvillier fascia and control of the lateral pedicles with antegrade neurovascular bundle dissection; (8) apical dissection and division of the dorsal vein and the urethra; (9) urethrovesical anastomosis.
Considering about 30% of dropout rate (under the assumption of 40% difference between HA/CMC treatment group and the control group based on previous similar study, by which the target enrollment for this trial was 60 subjects (30 subjects per group). The sample size was determined assuming a level of significance of α=0.05 (two-side) and a 80% statistical power of test. All patients were randomly assigned to either the HA/CMC treatment group (n=30) or the control group (n=30) using a computer-generated randomization table. The surgeon was blinded to treatment assignments before randomization. Patients were also blinded to their treatment group throughout the study. HA/CMC was applied in all port sites and the peritoneal incision line of the medial umbilical ligament with a single-use applicator attached to a sprayer that allowed for the precise application to the required sites. The amount of HA/CMC applied was 5 ml. Information regarding the duration of illness and medical history were collected at the time of enrollment (V0). Viscera slide ultrasound and plain X-ray were recorded at the time of the operation (V0) and 12 (V1) and 24 week (V2) after the operation.
The primary end point was the difference in excursion distance on viscera slide ultrasound between V0 and V2. The secondary end point was excursion distance on viscera slide ultrasound at V2 and the presence of restriction of viscera slide on ultrasound at V2.
Assessment of efficacy and safety Twelve and 24 weeks after the operation, bowel adhesion to the abdominal wall was evaluated by ultrasound and plain X-rays. We performed viscera slide ultrasound according to a technique that has been previously described. By dividing the abdomen into 5 segments and examining the viscera slide in each segment, a prediction of the extent of the adhesions was made for each patient. At the time of the viscera slide ultrasound, data were also collected on the location of the scars on the abdomen. The main point of interest was the distance of the longitudinal excursion of the selected area in relation to the fixed abdominal wall. Normal viscera sliding movement was defined as equal to or greater than 1 cm of longitudinal movement. Restricted viscera slide was defined as less than 1 cm of longitudinal movement during both normal and exaggerated respiration. The ultrasound was performed by two sonographers who had been well instructed for study assessment. The assessment by ultrasound was double-checked. The sonographer, radiologist and all accessor was blind to the randomization during the all study period.
Statistical Analysis The data for this study are expressed as mean ± standard deviation of the mean. The comparisons of the 2 groups were made using a chi-test, an independent Student's t test, or repeated measure ANOVA. P-values <0.05 were considered significant. Statistical calculations were carried out with IBM SPSS statistics, Version 21 (IBM Corp, Armonk, NY).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| hyaluronic acid-carboxymethylcellulose treatment group | Experimental | Drug: hyaluronic acid-carboxymethylcellulosethe HA/CMC treatment group after laparoscopic pelvic surgery |
| control group | No intervention | –the HA/CMC non-treatment group after laparoscopic pelvic surgery |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic pelvic surgery (radical prostatectomy).
Key exclusion criteria (1 listed)
- any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| hyaluronic acid-carboxymethylcellulose | Drug | hyaluronic acid-carboxymethylcellulose treatment group |
Primary outcome
the difference in excursion distance on viscera slide ultrasound between V0 and V2.
Time frame: within the first 6 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 May 2016.
- Derived from this study: PubMed 27286961Ha US, Koh JS, Cho KJ, Yoon BI, Lee KW, Hong SH, Lee JY. Hyaluronic acid-carboxymethylcellulose reduced postoperative bowel adhesions following laparoscopic urologic pelvic surgery: a prospective, randomized, controlled, single-blind study. BMC Urol. 2016 Jun 10;16(1):28. doi: 10.1186/s12894-016-0149-3.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing hyaluronic acid-carboxymethylcellulose in people with Prostate Cancer and Postoperative Adhesion, run by Bucheon St. Mary's Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 May 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the difference in excursion distance on viscera slide ultrasound between V0 and V2. (time frame: within the first 6 months after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02773251, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2016.